Retinal Degeneration


RetroSense Therapeutics Completes pre-IND Meeting for RST-001

RetroSense Therapeutics, a gene therapy company dedicated to vision restoration, announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research division of the FDA that took place on May 22 regarding RetroSense’s lead product candidate, RST-001 for vision restoration in retinal degenerative conditions.

WWJ Newsradio 950–05/24/2012